References
- Chen XJ, Li N, Huang YD, et al (2014). Factors for postoperative gallstone occurrence in patients with gastric cancer: a metaanalysis. Asian Pac J Cancer Prev, 15, 877-81. https://doi.org/10.7314/APJCP.2014.15.2.877
- Choi AR, Park JC, Kim J, et al (2013). High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol, 19, 5302-8. https://doi.org/10.3748/wjg.v19.i32.5302
- Duraker N, Celik AN (2001). The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol, 76, 266-71. https://doi.org/10.1002/jso.1044
- Gaarenstroom KN, Bonfrer JM, Kenter GG, et al (1995). Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer, 76, 807-13. https://doi.org/10.1002/1097-0142(19950901)76:5<807::AID-CNCR2820760515>3.0.CO;2-M
- Gartner U, Scheulen ME, Conradt C, et al (1998). Value of tumor-associated antigens CA 72-4 vs CEA and CA 19-9 in the follow-up after stomach cancer. Dtsch Med Wochenschr, 123, 69-73. https://doi.org/10.1055/s-2007-1023900
- Ikeguchi M, Katano K, Saitou H, et al (1997). Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology, 44, 866-71.
- Japanese Gastric Cancer Association (2011). Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 14, 101-12. https://doi.org/10.1007/s10120-011-0041-5
- Jung KW, Won YJ, Kong HJ, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res and Treat, 45,1-14. https://doi.org/10.4143/crt.2013.45.1.1
- Kodama I, Koufuji K, Kawabata S, et al (1995). The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg, 80, 45-8.
- Kodera Y, Yamamura Y, Torii A, et al (1996). The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol, 91, 49-53.
- Koenig A, Wojcieszyn J, Weeks BR, Modiano JF (2001). Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma. Vet Pathol, 38, 427-35. https://doi.org/10.1354/vp.38-4-427
- Koga T, Kano T, Souda K, Oka N, Inokuchi K(1987). The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg, 17, 342-7. https://doi.org/10.1007/BF02470632
- Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981). Specific antigen in serum of patients with colon carcinoma. Science, 212, 53-5. https://doi.org/10.1126/science.6163212
- Lee IK, Kim DH, Gorden DL, et al (2009). Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol, 16, 861-70. https://doi.org/10.1245/s10434-008-0294-3
- Lee JH (2013). Clinical usefulness of serum CYFRA 21-1 in patients with colorectal cancer. Nucl Med Mol Imaging, 47, 181-7. https://doi.org/10.1007/s13139-013-0218-4
- Liu X, Cai H, Wang Y (2012). Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol, 10, 1-9. https://doi.org/10.1186/1477-7819-10-1
- Mattar R, Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA (2002). Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo, 57, 89-92. https://doi.org/10.1590/S0041-87812002000300001
- Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS (1986). The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer, 58, 603-10. https://doi.org/10.1002/1097-0142(19860801)58:3<603::AID-CNCR2820580302>3.0.CO;2-K
- Molina R, Filella X, Auge JM, et al (2003). Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol, 24, 209-18. https://doi.org/10.1159/000074432
- Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K (2004). Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer, 91, 873-8. https://doi.org/10.1038/sj.bjc.6602074
- Qin H, Qu LL, Liu H, Wang SS, Gao HJ (2013). Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4205-8. https://doi.org/10.7314/APJCP.2013.14.7.4205
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA: A Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Sisik A, Kaya M, Bas G, Basak F, Alimoglu O (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94. https://doi.org/10.7314/APJCP.2013.14.7.4289
- Ubukata H, Katano M, Motohashi G, et al (2003). Evaluation of CA72-4 as a tumor marker in patients with gastric cancer. Gan To Kagaku Ryoho, 30, 1821-4.
- Ucar E, Semerci E, Ustun H, et al (2008). Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-84. https://doi.org/10.1007/s12325-008-0100-4
- Waldum HL, Aase S, Kvetnoi I, et al (1998). Neuroendocrine differentiation in human gastric carcinoma. Cancer, 83, 435-44. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<435::AID-CNCR11>3.0.CO;2-X
- Wieskopf B, Demangeat C, Purohit A, et al (1995). Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest, 108, 163-9. https://doi.org/10.1378/chest.108.1.163
- Yoshioka T, Yamaguchi K, Kubota K, et al (2003). Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med, 44, 690-9.
- Zeltzer PM, Marangos PJ, Evans AE, Schneider SL (1986). Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer, 57, 1230-4. https://doi.org/10.1002/1097-0142(19860315)57:6<1230::AID-CNCR2820570628>3.0.CO;2-#
- Zhang HQ, Wang RB, Yan HJ, et al (2012). Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev, 13, 199-203. https://doi.org/10.7314/APJCP.2012.13.1.199
- Zhu SJ, Zhang Y, Yu YH, et al (2013). FDG PET-CT in non-small cell lung cancer: relationship between primary tumor fdg uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-29. https://doi.org/10.7314/APJCP.2013.14.5.2925
Cited by
- Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6295
- Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9367
- Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10267
- Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3867
- The tumor marker CA 72-4 pp.2198-0713, 2017, https://doi.org/10.1007/s40664-017-0212-2
- Effects of different methods of anesthesia and analgesia on immune function and serum tumor marker levels in critically ill patients vol.14, pp.3, 2017, https://doi.org/10.3892/etm.2017.4762
- Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial vol.40, pp.3, 2018, https://doi.org/10.1177/1010428318764007